Morning or afternoon? timing may boost kidney cancer treatment
NCT ID NCT07338981
First seen Jan 20, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon makes them work better or cause fewer side effects in adults with advanced kidney cancer. About 142 participants will be randomly assigned to morning or afternoon treatment. The goal is to see if timing affects overall survival and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KIDNEY CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
Conditions
Explore the condition pages connected to this study.